Operating cash flow increased 463.3%
Operating cash flow changed +463.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Operating cash flow changed +463.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed +39.7% from the comparable as-filed period.
Operating margin changed +2964 basis points from the comparable as-filed period.
Revenue changed +34.4% from the comparable as-filed period.
Cash & equivalents changed +42.6% from the comparable as-filed period.
Gross profit changed +35.4% from the comparable as-filed period.
Research & development changed +22.0% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Inventory / revenue changed -1752 basis points from the comparable as-filed period.
Inventory changed -28.7% from the comparable as-filed period.
Working capital / assets changed +1097 basis points from the comparable as-filed period.
Operating cash-flow margin changed +2071 basis points from the comparable as-filed period.
Receivables / revenue changed -3800 basis points from the comparable as-filed period.
Current liabilities changed -11.2% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Current assets changed +12.3% from the comparable as-filed period.
SBC / revenue changed -138 basis points from the comparable as-filed period.
Current ratio changed +26.5% from the comparable as-filed period.
Stock-based compensation changed +23.5% from the comparable as-filed period.
Working capital changed +330.0% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
Total assets changed +7.7% from the comparable as-filed period.
Gross margin changed +34 basis points from the comparable as-filed period.
Shares outstanding changed +5.4% from the comparable as-filed period. The change ranks at the 60th percentile of 5 prior comparable changes.
Trade receivables changed -5.3% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
R&D / revenue changed -134 basis points from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.